Clinical Trials Logo

Clinical Trial Summary

Mesothelioma is an aggressive form of cancer. Treatments are available, but for many people, a cure isn't possible. This thesis is to assess the efficacy and safety of switch-maintenance Gemcitabine in Mesothelioma patients after first line chemotherapy (Pemetrexed-Platinum)


Clinical Trial Description

Malignant pleural mesothelioma is a rare but aggressive cancer of the pleural lining. Malignant pleural mesothelioma accounted for 30,870 new cancer cases and 26,278 deaths worldwide in 2020. In Egypt, Malignant pleural mesothelioma accounted for 337 new cases and 307 deaths in 2020. Long-term exposure to asbestos is a well-established risk factor for Malignant pleural mesothelioma. It accounts for almost 80% of cases. Malignant pleural mesothelioma is classified into three histologic subtypes: epithelioid, sarcomatoid, and biphasic. Epithelioid histology confers the most favorable prognosis and sarcomatoid the least. The majority of patients with Malignant pleural mesothelioma present with breathlessness, chest pain or both. Other symptoms include fatigue, anorexia, weight loss, sweats and malaise. Radiological imaging should be undertaken in all patients as it can provide valuable diagnostic and staging information. Further investigation of suspected Malignant pleural mesothelioma requires sampling of pleural fluid for biochemical and cytological examination. Biopsies are usually required to confirm the diagnosis and identify the histological sub-type. Patients with Malignant pleural mesothelioma should be managed by an experienced multidisciplinary team. Treatment options include surgery, radiation therapy and chemotherapy. Front line polychemotherapy is considered the standard of care, whereas single agent chemotherapy has shown limited efficacy with disappointing response rates. A pivotal trial led to the establishment of Cisplatin and Pemetrexed as standard first line regimen for unresectable Malignant pleural mesothelioma. A recent phase II trial from Cancer and Leukemia Group B showed that maintenance Pemetrexed after 4 to 6 cycles of doublet chemotherapy induction did not prolong progression free survival over placebo. Adding Bevacizumab to first line platinum doublet resulted in an overall survival and progression free survival gain in the phase III French trial MAPS .Bevacizumab was continued as maintenance every three weeks following completion of six cycles of chemotherapy. In a phase III trial NVALT 5 , Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy showed no benefit in time to progression. First line Nivolumab plus Ipilimumab in phase III trial checkmate 743 provided significant and clinically meaningful improvements in overall survival versus standard of care chemotherapy. Unfortunately, nearly all patients progress during or after first-line therapy, and no standard second line recommended treatments exist after platinum based regimen. Retreatment with pemetrexed, eventually associated with platinum compound, may be offered in patients who achieved durable disease control more than 6 months with first line chemotherapy. Single agent chemotherapy with Vinorelbine or Gemcitabine is the preferred choice as second line treatment , mainly based on retrospective analyses or small phase II trials. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05660616
Study type Interventional
Source Ain Shams University
Contact Abanoub Samir
Phone 0201002869267
Email abanoob_sk@yahoo.com
Status Recruiting
Phase Phase 2
Start date April 1, 2023
Completion date December 2024

See also
  Status Clinical Trial Phase
Recruiting NCT06037941 - Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma N/A
Completed NCT01675765 - Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma Phase 1
Withdrawn NCT04201145 - Pembrolizumab + Defactinib In Pleural Mesothelioma Phase 1
Completed NCT03048474 - Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma Phase 2
Completed NCT02369198 - MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC Phase 1
Terminated NCT01870609 - Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma Phase 2
Active, not recruiting NCT00886028 - Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma Phase 2
Completed NCT00272558 - Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma Phase 2
Active, not recruiting NCT02436733 - Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM Phase 2
Completed NCT04843007 - Alvopem® (Pemetrexed) Safety Assessment
Completed NCT01721018 - Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma. Phase 1/Phase 2
Active, not recruiting NCT00797719 - Short Neoadjuvant Hemithoracic IMRT for MPM Phase 1/Phase 2
Completed NCT00386815 - Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma Phase 2
Recruiting NCT03715933 - Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas Phase 1
Completed NCT04775446 - Evaluation of the Clinical/Biological Characteristics, Efficacy and Safety of Patients With Malignant Pleural Mesothelioma, Treated by Immunotherapy
Completed NCT01644994 - Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma Phase 1/Phase 2
Completed NCT01865045 - Pharmacogenetics Of Vinorelbine In Malignant Pleural Mesothelioma Patients
Completed NCT00571298 - Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma Phase 1
Recruiting NCT01343264 - Trimodality Therapy for Malignant Pleural Mesothelioma N/A
Active, not recruiting NCT04162015 - A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma Phase 1